Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status

European Journal of Cancer

Volumn 48, Issue 11, 2012, Pages 1739-1749

  Eisenhofer, Graeme ^a   Lenders, Jacques W M ^a,b   Siegert, Gabriele ^a   Bornstein, Stefan R ^a   Friberg, Peter ^c   Milosevic, Dragana ^d   Mannelli, Massimo ^e   Linehan, W Marston ^f   Adams, Karen ^g   Timmers, Henri J ^b,g   Pacak, Karel ^g  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF FLORENCE   (Italy)

^f NATIONAL CANCER INSTITUTE   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Catecholamines; Dopamine; Metanephrines; Metastases; Methoxytyramine; Paraganglioma; Pheochromocytoma; Succinate dehydrogenase type B

Indexed keywords

CATECHOLAMINE; METHOXYTYRAMINE; NORADRENALIN; NORMETADRENALIN; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CATECHOLAMINE BLOOD LEVEL; CHILD; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR LOCALIZATION; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; ADULT; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NORMETANEPHRINE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RISK FACTORS; SUCCINATE DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862772345     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.07.016     Document Type: Article

References (32)

1. G. Eisenhofer, S.R. Bornstein, and F.M. Brouwers Malignant pheochromocytoma: current status and initiatives for future progress Endocr Relat Cancer 11 3 2004 423 436
2. A. Chrisoulidou, G. Kaltsas, I. Ilias, and A.B. Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr Relat Cancer 14 3 2007 569 585
3. F.M. Brouwers, E.F. Petricoin 3rd, and L. Ksinantova Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma Endocr Relat Cancer 12 2 2005 263 272
4. F.M. Brouwers, A.G. Elkahloun, and P.J. Munson Gene expression profiling of benign and malignant pheochromocytoma Ann NY Acad Sci 1073 2006 541 556
5. V.E. Strong, T. Kennedy, and H. Al-Ahmadie Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis Surgery 143 6 2008 759 768
6. I. Suh, D. Shibru, and G. Eisenhofer Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling Ann Surg 250 6 2009 983 990
7. E. Thouennon, A. Pierre, and Y. Tanguy Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival Endocr Relat Cancer 17 3 2010 637 651
8. J. Waldmann, V. Fendrich, and J.P. Holler Microarray analysis reveals differential expression of benign and malignant pheochromocytoma Endocr Relat Cancer 17 2010 743 756
9. G.Y. Meyer-Rochow, N.E. Jackson, and J.V. Conaglen MicroRNA profiling of benign and malignant pheochromocytoma identifies novel diagnostic and therapeutic targets Endocr Relat Cancer 17 2010 835 846
10. H. John, W.H. Ziegler, D. Hauri, and P. Jaeger Pheochromocytomas: can malignant potential be predicted? Urology 53 4 1999 679 683
11. L. Amar, J. Bertherat, and E. Baudin Genetic testing in pheochromocytoma or functional paraganglioma J Clin Oncol 23 34 2005 8812 8818
12. F.M. Brouwers, G. Eisenhofer, and J.J. Tao High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing J Clin Endocrinol Metab 91 11 2006 4505 4509
13. P.A. Tippett, A.J. McEwan, and D.M. Ackery A re-evaluation of dopamine excretion in phaeochromocytoma Clin Endocrinol (Oxf) 25 4 1986 401 410
14. C. Proye, M. Vix, A. Goropoulos, P. Kerlo, and M. Lecomte-Houcke High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991 J Endocrinol Invest 15 9 1992 651 663
15. W. Januszewicz, B. Wocial, A. Januszewicz, P. Gryglas, and A. Prejbisz Dopamine and dopa urinary excretion in patients with pheochromocytoma - diagnostic implications Blood Press 10 4 2001 212 216
16. E. van der Harst, W.W. de Herder, and R.R. de Krijger The value of plasma markers for the clinical behaviour of phaeochromocytomas Eur J Endocrinol 147 1 2002 85 94
17. G. Eisenhofer, D.S. Goldstein, and P. Sullivan Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine J Clin Endocrinol Metab 90 2005 2068 2075
18. G. Eisenhofer, D.S. Goldstein, and R. Stull Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase Clin Chem 32 11 1986 2030 2033
19. J.W. Lenders, G. Eisenhofer, and I. Armando Determination of metanephrines in plasma by liquid chromatography with electrochemical detection Clin Chem 39 1 1993 97 103
20. F. Rao, H.R. Keiser, and D.T. O'Connor Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment Hypertension 36 6 2000 1045 1052
21. L. Amar, S. Peyrard, and P. Rossignol Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas Ann NY Acad Sci 1073 2006 383 391
22. M. Ayala-Ramirez, L. Feng, and M.M. Johnson Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators J Clin Endocrinol Metab 96 3 2011 717 725
23. W. Remine, G. Chong, J. van Heerden, S. Sheps, and E.J. Harrison Current management of pheochromocytoma Ann Surg 179 1974 740 748
24. C.A. Proye, M. Vix, and S. Jansson The pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 18 4 1994 467 472
25. R.E. Goldstein, J.A. O'Neill Jr. , and G.W. Holcomb 3rd Clinical experience over 48 years with pheochromocytoma Ann Surg 229 6 1999 755 764 discussion 764-756
26. M. Mannelli, L. Ianni, A. Cilotti, and A. Conti Pheochromocytoma in Italy: a multicentric retrospective study Eur J Endocrinol 141 6 1999 619 624
27. E. Edstrom Elder, A.L. Hjelm Skog, A. Hoog, and B. Hamberger The management of benign and malignant pheochromocytoma and abdominal paraganglioma Eur J Surg Oncol 29 3 2003 278 283
28. L. Amar, A. Servais, and A.P. Gimenez-Roqueplo Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma J Clin Endocrinol Metab 90 4 2005 2110 2116
29. F. Feng, Y. Zhu, and X. Wang Predictive factors for malignant pheochromocytoma: analysis of 136 patients J Urol 185 5 2011 1583 1590
30. J. Park, C. Song, and M. Park Predictive characteristics of malignant pheochromocytoma Korean J Urol 52 4 2011 241 246
31. H.J. Timmers, K. Pacak, and T.T. Huynh Biochemically silent abdominal paragangliomas in patients with mutations in the Sdhb gene J Clin Endocrinol Metab 93 2008 4826 4832
32. H.J. Timmers, A. Kozupa, and C.C. Chen Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 16 2007 2262 2269